Amphetamine; amphetamine aspartate/dextroamphetamine sulfate - Generic Drug Details

What are the generic sources for amphetamine; amphetamine aspartate/dextroamphetamine sulfate and what is the scope of freedom to operate?

Amphetamine; amphetamine aspartate/dextroamphetamine sulfate is the generic ingredient in five branded drugs marketed by Tris Pharma Inc and is included in two NDAs. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amphetamine; amphetamine aspartate/dextroamphetamine sulfate has twenty-one patent family members in fourteen countries.

One supplier is listed for this compound.

Summary for amphetamine; amphetamine aspartate/dextroamphetamine sulfate

International Patents:	21
US Patents:	11
Tradenames:	5
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
DailyMed Link:	amphetamine; amphetamine aspartate/dextroamphetamine sulfate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for amphetamine; amphetamine aspartate/dextroamphetamine sulfate

Constraining patent/regulatory exclusivity:

8,062,667

Dosage:

SUSPENSION, EXTENDED RELEASE;ORAL

Constraining patent/regulatory exclusivity:

8,747,902

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for amphetamine; amphetamine aspartate/dextroamphetamine sulfate

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DYANAVEL XR 5	Extended-release Tablets	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	5 mg, 10 mg, 15 mg and 20 mg	210526	1	2025-01-22

US Patents and Regulatory Information for amphetamine; amphetamine aspartate/dextroamphetamine sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tris Pharma Inc	DYANAVEL XR 10	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-002	Nov 4, 2021		RX	Yes	No	9,675,704		Y
Tris Pharma Inc	DYANAVEL XR 20	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-004	Nov 4, 2021		RX	Yes	Yes	8,747,902		Y
Tris Pharma Inc	DYANAVEL XR 5	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-001	Nov 4, 2021		RX	Yes	No	11,590,081		Y
Tris Pharma Inc	DYANAVEL XR 5	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-001	Nov 4, 2021		RX	Yes	No	8,337,890		Y

International Patents for amphetamine; amphetamine aspartate/dextroamphetamine sulfate

Country	Patent Number	Title	Estimated Expiration
Spain	2378573
Japan	2009530298
Japan	5479086
Russian Federation	2008140944	КОМПОЗИЦИИ С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ КОМПЛЕКСЫ ЛЕКАРСТВЕННОЕ ВЕЩЕСТВО-ИОНООБМЕННАЯ СМОЛА

Market Dynamics and Financial Trajectory for Amphetamine and Related Formulations

Last updated: February 23, 2026

How is the Amphetamine Market Structured?

The amphetamine market primarily comprises medical use formulations, notably dextroamphetamine sulfate and amphetamine aspartate/dextroamphetamine sulfate. These drugs are predominantly used in attention deficit hyperactivity disorder (ADHD) and narcolepsy treatment.

Key Market Segments:

• Prescription medications: Dextroamphetamine sulfate (e.g., Dexedrine), mixed amphetamine salts (e.g., Adderall), and amphetamine aspartate/dextroamphetamine sulfate.
• Recreational and illicit use: Contributes to demand fluctuations, with illegal markets impacting supply chains and pricing.

Approvals and Patent Landscape:

• Many formulations are off-patent, exposing market competition to generics.
• Patent expirations have occurred in recent years, increasing generic penetration.
• Several formulations are approved by regulators such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

How Have Market Dynamics Shifted Recently?

Regulatory Changes:

• Stricter controls on prescribing due to abuse potential.
• Rescheduling of certain formulations from prescription-only to controlled substances, affecting supply and demand curves.

Socioeconomic Factors:

• Rising ADHD diagnoses elevate prescription volumes.
• Increased awareness and reduced stigma drive treatment acceptance in adult populations.

Supply Chain Constraints:

• Raw material shortages, including pseudoephedrine and ephedrine used in their synthesis.
• Disruptions due to regulatory crackdowns on precursor chemicals.

Market Competition:

• Entry of generic manufacturers has driven down prices.
• Limited innovation in formulation; focus on manufacturing efficiency.

Pricing Trends:

Year	Average Retail Price (per 30-day supply)	Price Trend
2018	$50	Stable
2020	$45	Slight decrease
2022	$40	Continued decline due to generics

(Note: Prices vary by formulation and region, with typical U.S. retail prices showing downward pressure.)

What Is the Financial Trajectory for Amphetamine?

Market Size and Revenue:

• Global market size: Estimated at approximately USD 2.1 billion in 2022.
• Compound annual growth rate (CAGR): Projected at around 3-4% from 2023 to 2030 due to increasing diagnoses and expanding use in adult populations.

Revenue Drivers:

• Growth in prescription volumes, especially in North America.
• Market share gains by generic manufacturers diminishing the revenue potential for branded formulations.

R&D and Investment Trends:

• Low innovation activity; most firms focus on manufacturing efficiencies.
• Potential future investment in abuse-deterrent formulations or extended-release systems to mitigate misuse.

Future Market Constraints:

• Policy and regulatory risks, including tighter controls and legal crackdowns.
• Patent cliff for key formulations, increasing price competition.
• Patent litigation and biosimilar or generic entry threaten margins.

How Do Price and Regulation Interact?

The regulatory environment directly affects pricing. Tight controls on prescribing and scheduling reduce access, limiting revenue. Conversely, patent expirations and the subsequent increase in generics lower prices but expand volume.

Regulatory Impact	Effect
Stricter prescription rules	Decrease in market volume
Rescheduling or scheduling as controlled substances	Price stabilization or reduction
Patent expirations, increases in generic entries	Price erosion

Conclusion: Market Outlook and Investment Considerations

The amphetamine market remains stable with moderate growth driven by rising diagnoses and expanded treatment in adults. Patent expirations and generics are the primary factors constraining profitability. Regulatory enforcement and supply chain disruptions pose ongoing risks.

Investors should monitor legislative developments, particularly regarding abuse-deterrent formulations and potential shifts in prescribing guidelines. Companies investing in R&D for improved formulations may retain competitive advantages in this saturated and highly regulated market.

Key Takeaways

• The global amphetamine market is valued at USD 2.1 billion as of 2022, with a CAGR of approximately 3-4%.
• Patent expirations and the proliferation of generics have lowered prices and margins.
• Regulatory actions significantly influence market size and pricing strategies.
• Demand growth is driven by increased ADHD diagnoses and adult treatment acceptance.
• Innovation focus is on abuse-deterrent and extended-release formulations.

FAQs

1. What are the main formulations of amphetamine used medically?
   Dextroamphetamine sulfate and mixed amphetamine salts. Amphetamine aspartate/dextroamphetamine sulfate are formulations combining active isomers for specific therapeutic effects.

2. How do patent expirations affect the market?
   Patent expirations lead to increased generic competition, reducing prices and margins for branded products.

3. What regulatory risks impact this market?
   Rescheduling as controlled substances, prescribing restrictions, and enforcement on precursor chemicals influence supply and demand.

4. Is innovation occurring in the market?
   Little innovation in active ingredients; focus is on abuse-deterrent and extended-release formulations.

5. What is the outlook for future revenue growth?
   Moderate growth driven by increased diagnosis rates; however, margins are under pressure due to patent cliffs and generics.

---

Citations

[1] Statista. (2023). Market size of the global ADHD drugs market.
[2] U.S. Food and Drug Administration (FDA). (2022). Controlled Substance Schedules.
[3] IMS Health. (2022). Price trends for ADHD medications.
[4] EvaluatePharma. (2022). Pharmaceutical market analysis.
[5] GlobeNewswire. (2023). Trends in prescription volumes for stimulant medications.